

ARUP Laboratories provides its clients with an analytical service that evaluates the economic feasibility of performing specific tests in-house (make) vs. sending these same tests to a reference laboratory partner (buy).
Offering this unique cost-accounting tool to its clients at no cost, ARUP provides both information and data, focusing on high-volume and high-cost spending to facilitate make vs. buy decisions. ARUP clients can thus:
The ARUP Insource Advantage Report analyzes current and historical costs as well as volume information to assist ARUP clients in managing their send-out purchase services in the most financially feasible way. The Insource Advantage Report is a valuable tool that complements the make vs. buy process and aids in the economic decision-making process. With data generated by the report, clients receive specific information, including:
The Insource Advantage Report helps ARUP clients identify appropriate expense distribution, and as a result, manage appropriate make vs. buy decisions.
ARUP’s active research and development in pathology and laboratory medicine allows it to develop new technologies and tests. ARUP is one of the industry leaders in molecular technology in both the clinical and anatomic pathology arenas.
ARUP assists its clients in bringing tests in-house by:
Collaborations on method validation are also considered on a case-by-case basis for projects of mutual interest and benefit.
By utilizing ARUP’s Insource Advantage, ARUP clients:
Clients benefit from ARUP's clinical experience where methodologies and data validation are developed in a patient-care environment.
ARUP can also provide an ATOP® report to analyze medical test utilization patterns within a client organization.